Back

Rare variants and survival of patients with idiopathic pulmonary fibrosis

Alonso-Gonzalez, A.; Jaspez, D.; Lorenzo-Salazar, J. M.; Ma, S.-F.; Strickland, E.; Mychaleckyj, J.; Kim, J. S.; Huang, Y.; Adegunsoye, A.; Oldham, J. M.; Stewart, I.; Molyneaux, P. L.; Maher, T. M.; Wain, L. V.; Allen, R. J.; Jenkins, R. G.; Kropsky, J. A.; Yaspan, B.; Blackwell, T. S.; Zhang, D.; Garcia, C. K.; Martinez, F. J.; Noth, I.; Flores, C.

2024-10-15 genetic and genomic medicine
10.1101/2024.10.12.24315151 medRxiv
Show abstract

BackgroundThe clinical course of idiopathic pulmonary fibrosis (IPF) is highly variable and unpredictable, with multiple genetic variants influencing IPF outcomes. Notably, rare pathogenic variants in telomere-related genes are associated with poorer clinical outcomes in these patients. Here we assessed whether rare qualifying variants (QVs) in monogenic adult-onset pulmonary fibrosis (PF) genes are associated with IPF survival. Using polygenic risk scores (PRS), we also evaluated the influence of common IPF risk variants in individuals carrying these QVs. MethodsWe identified QVs in telomere and non-telomere genes linked to monogenic PF forms using whole-genome sequences (WGS) from 888 Pulmonary Fibrosis Foundation Patient Registry (PFFPR) individuals. We also derived a PRS for IPF (PRS-IPF) from 19 previously published common sentinel IPF variants. Using regression models, we then examined the mutual relationships of QVs and PRS-IPF and their association with survival. Validation of results was sought in WGS from an independent IPF study (PROFILE, n=472), and results from the two cohorts were meta-analyzed. ResultsCarriers of QVs in monogenic adult-onset PF genes, representing nearly 1 out of 6 IPF patients, were associated with lower PRS-IPF (Odds Ratio [OR]: 1.79; 95% Confidence Interval [CI]: 1.15-2.81; p=0.010) and shorter survival (Hazard Ratio [HR]: 1.53; 95% CI: 1.12-2.10; p=7.3x10-3). Notably, carriers of pathogenic variants at telomere genes showed the strongest association with survival (HR: 1.76; 95% CI: 1.13-2.76; p=0.013). The meta-analysis of the results showed a consistent direction of effect across both cohorts. ConclusionsWe revealed the opposite effects of QVs and PRS-IPF on IPF survival. Thus, a distinct IPF molecular subtype might be defined by QVs in monogenic adult-onset PF genes. Assessing the carrier status for QVs and modelling PRS-IPF promises to further contribute to predicting disease progression among IPF patients.

Matching journals

The top 1 journal accounts for 50% of the predicted probability mass.

1
European Respiratory Journal
54 papers in training set
Top 0.1%
50.2%
50% of probability mass above
2
American Journal of Respiratory and Critical Care Medicine
39 papers in training set
Top 0.1%
6.8%
3
Genome Medicine
154 papers in training set
Top 2%
3.6%
4
Nature Communications
4913 papers in training set
Top 47%
2.1%
5
Scientific Reports
3102 papers in training set
Top 53%
1.9%
6
Thorax
32 papers in training set
Top 0.4%
1.9%
7
JCI Insight
241 papers in training set
Top 3%
1.7%
8
Human Molecular Genetics
130 papers in training set
Top 2%
1.7%
9
EBioMedicine
39 papers in training set
Top 0.3%
1.7%
10
Gut
36 papers in training set
Top 0.5%
1.7%
11
Rheumatology
21 papers in training set
Top 0.3%
1.5%
12
ERJ Open Research
44 papers in training set
Top 0.5%
1.3%
13
Journal of Clinical Investigation
164 papers in training set
Top 4%
1.2%
14
Critical Care
14 papers in training set
Top 0.4%
1.2%
15
Journal of Translational Medicine
46 papers in training set
Top 2%
1.1%
16
American Journal of Respiratory Cell and Molecular Biology
38 papers in training set
Top 0.6%
0.9%
17
Journal of Allergy and Clinical Immunology
25 papers in training set
Top 0.6%
0.9%
18
Bioinformatics
1061 papers in training set
Top 9%
0.7%
19
Frontiers in Immunology
586 papers in training set
Top 8%
0.7%
20
Genetics in Medicine
69 papers in training set
Top 1%
0.7%
21
Pediatric Pulmonology
14 papers in training set
Top 0.4%
0.7%
22
PLOS ONE
4510 papers in training set
Top 71%
0.6%
23
Arthritis & Rheumatology
33 papers in training set
Top 0.6%
0.6%
24
BMC Medical Genomics
36 papers in training set
Top 2%
0.6%
25
Clinical Immunology
21 papers in training set
Top 0.7%
0.6%